Press Releases | Longboard Pharmaceuticals

Skip to main navigation

Corporate Menu

About
Our Approach
Patients
Investors
Longboard Life
- Overview
- Culture and Benefits
Contact

Press Releases

Year

November 21, 2023

Longboard Pharmaceuticals’ Presence at American Epilepsy Society (AES) Annual Meeting Reinforces Ongoing Commitment to the Rare Epilepsy Community

November 3, 2023

Longboard Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

November 2, 2023

Longboard Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2023 Financial Results

November 1, 2023

Longboard Pharmaceuticals to Present at Three Upcoming Investor Conferences in November

October 5, 2023

Longboard Pharmaceuticals Announces Speakers for Investor & Analyst Event in New York on October 11, 2023

September 19, 2023

Longboard Pharmaceuticals to Host Investor & Analyst Event in New York on October 11, 2023

August 31, 2023

Longboard Pharmaceuticals to Participate in Three Upcoming Investor Conferences

August 30, 2023

Longboard Pharmaceuticals to Present Data at Upcoming Medical Meetings

August 23, 2023

Longboard Pharmaceuticals Completes Enrollment of Phase 1b/2a PACIFIC Study Evaluating LP352 for the Treatment of Developmental and Epileptic Encephalopathies

August 3, 2023

Longboard Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2023 Financial Results

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 19

©2023 Longboard Pharmaceuticals Privacy Policy | Terms of Use

Corporate Menu

About
Our Approach
Patients
Investors
Longboard Life
- Overview
- Culture and Benefits
Contact